STOCK TITAN
  1. Home
  2. Sec-filings
  3. RXRX
  4. [Form 4] RECURSION PHARMACEUTICALS, INC. Insider Trading Activity

Recursion (NASDAQ: RXRX) CSO sees 26K shares withheld for taxes

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

RECURSION PHARMACEUTICALS, INC. (RXRX) reported that Chief Scientific Officer David Hallett had 26,657 shares of Class A common stock withheld on 2026-08-17 to satisfy tax withholding and remittance obligations related to the net settlement of restricted stock units. This reduced his position for tax purposes only; his direct holdings after this event are 1,043,837 shares of Class A common stock.

Positive

  • None.

Negative

  • None.
Insider Hallett David
Role Chief Scientific Officer
Type Security Shares Price Value
Tax Withholding Class A Common Stock F1 26,657 $3.16 $84K
Holdings After Transaction: Class A Common Stock — 1,043,837 shares (Direct)
Footnotes (1)
  1. F1. Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
Shares withheld for taxes 26,657 shares Class A Common Stock withheld to satisfy tax obligations on 2026-08-17
Price per share $3.16 per share Value used for the tax-withholding disposition of 26,657 shares
Shares held after transaction 1,043,837 shares Direct ownership of Class A Common Stock by David Hallett after withholding
restricted stock units financial
"in connection with the net settlement of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
net settlement financial
"in connection with the net settlement of restricted stock units"
tax withholding financial
"withheld by the Issuer to satisfy its tax withholding and remittance obligations"
Tax withholding is the practice of taking a portion of a payment—such as wages, dividends, or sale proceeds—before it reaches the recipient and sending that portion to the tax authority as an advance on the recipient’s eventual tax bill. For investors it matters because withholding reduces immediate cash received and affects after‑tax returns, estimated tax payments, and whether you may owe more or receive a refund when taxes are finally calculated, like having a small automatic savings set aside for your tax bill.

FAQ

What insider transaction did RXRX Chief Scientific Officer David Hallett report?
David Hallett reported that 26,657 RXRX Class A shares were withheld on 2026-08-17 to cover tax obligations from net-settled restricted stock units, rather than being sold in an open-market transaction.

Was the August 17, 2026 RXRX Form 4 a market sale of shares?
No. The Form 4 states the 26,657 shares were withheld by Recursion Pharmaceuticals to satisfy tax withholding obligations upon net settlement of restricted stock units, not sold on the open market.

How many RXRX shares does David Hallett hold after the reported transaction?
Following the tax-withholding transaction, David Hallett directly holds 1,043,837 shares of Recursion Pharmaceuticals Class A common stock, as reported in the Form 4’s post-transaction ownership figure.

What price per share is associated with the RXRX tax-withholding transaction?
The Form 4 lists a price of $3.16 per share for the 26,657 shares withheld to satisfy tax obligations related to the net settlement of restricted stock units.

Does the RXRX Form 4 indicate use of a Rule 10b5-1 trading plan?
No. The filing’s Rule 10b5-1 checkbox is not marked as affirmative, and the footnote describes only tax withholding on restricted stock units, not trading under a pre-arranged plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hallett David
(Last)(First)(Middle)
C/O RECURSION PHARMACEUTICALS
41 S. RIO GRANDE STREET
(Street)
SALT LAKE CITY UTAH 84101
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Scientific Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Common Stock08/17/2026F(1)26,657D$3.161,043,837D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
Remarks:
/s/Jonathan Golightly, attorney-in-fact08/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR